As a result, human monoclonal anti-PCSK9 antibodies have proven effective in lowering LDL-C levels and atherosclerotic cardiovascular disease (ASCVD) risk, particularly in individuals with severe phenotypes or resistance to lipid-lowering therapies (LLT). This evidence concerns the gene PCSK9 and atherosclerosis.